All In Biotech

Free tool

FAERS Monitor: Romvimza

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 219304 or its brand name (Romvimza, Vimseltinib). Reports on generic versions are filed under their own applications.

Reports

549

Serious

85

15% of reports

Hospitalization

21

Death reported

1

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • fatigue136
  • swelling face69
  • pruritus63
  • periorbital swelling60
  • peripheral swelling51
  • product use issue45
  • arthralgia42
  • nausea42
  • rash42
  • eye swelling40
  • headache39
  • product dose omission issue34
  • hepatic enzyme increased32
  • asthenia30
  • pain28

Reports by year received

View as table
YearReports
20212
20221
2025313
2026233

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,610 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
periorbital swellingSignal60410.9323.123,876
eye swellingSignal4041.230.61,531
swelling faceSignal6940.632.62,634
hepatic enzyme increasedSignal3218.012.9498
peripheral swellingSignal5112.79.8541
product use issueSignal459.26.9322
fatigueSignal1366.75.8678
pruritusSignal636.35.0280
product dose omission issueSignal344.43.288
arthralgiaSignal423.92.988
rashSignal423.72.881
astheniaSignal303.12.240
headacheSignal392.41.831
nauseaSignal422.01.522
pain281.71.28

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.